Sera Prognostics (NASDAQ:SERA) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Sera Prognostics (NASDAQ:SERA) issued its earnings results on Wednesday. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.03), FiscalAI reports. Sera Prognostics had a negative return on equity of 41.02% and a negative net margin of 56,385.97%.The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.07 million.

Sera Prognostics Trading Up 1.5%

NASDAQ:SERA traded up $0.03 on Wednesday, reaching $2.02. The stock had a trading volume of 27,687 shares, compared to its average volume of 52,816. The company has a 50-day moving average of $2.00 and a 200 day moving average of $2.13. The stock has a market cap of $79.10 million, a P/E ratio of -3.11 and a beta of 0.96. Sera Prognostics has a 12-month low of $1.56 and a 12-month high of $3.95.

Insider Activity

In related news, CEO Zhenya Lindgardt sold 20,755 shares of the business’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $2.08, for a total value of $43,170.40. Following the transaction, the chief executive officer owned 871,999 shares in the company, valued at approximately $1,813,757.92. The trade was a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 27,755 shares of company stock worth $57,840 over the last 90 days. 11.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Sera Prognostics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Cetera Investment Advisers acquired a new stake in shares of Sera Prognostics during the fourth quarter worth approximately $74,000. Barclays PLC grew its holdings in Sera Prognostics by 267.4% during the 4th quarter. Barclays PLC now owns 36,722 shares of the company’s stock worth $108,000 after acquiring an additional 26,726 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Sera Prognostics in the 4th quarter worth about $203,000. Lido Advisors LLC acquired a new stake in shares of Sera Prognostics in the 3rd quarter valued at about $68,000. Finally, Citadel Advisors LLC raised its stake in shares of Sera Prognostics by 1.9% in the 3rd quarter. Citadel Advisors LLC now owns 653,746 shares of the company’s stock valued at $2,000,000 after purchasing an additional 12,439 shares in the last quarter. 54.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on SERA. Craig Hallum began coverage on Sera Prognostics in a research report on Thursday, June 4th. They set a “buy” rating and a $6.00 price target on the stock. Weiss Ratings downgraded shares of Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $5.50.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.